The new prostate cancer drug ‘Erleada’ can now be prescribed at general hospitals in Korea

According to industry sources Janssen Korea’s metastatic hormone-sensitive prostate cancer (mHSPC) treatment Erleada (apalutamide) passed the drug committees (DCs) of tertiary hospitals in Korea including the Seoul National University Hospital and Asan Medical Center, including emergency DC meetings, a total of 60 medical institutions generated a prescription code for Enhertu.

With the drug’s reimbursement listing last month, the approval is expected to quickly lead to actual Erleada prescriptions in the field.

Erleada is an androgen receptor targeted agent and a latecomer that